Uncategorized
Systemic therapy tops implants in long-term treatment of uveitis
A 7-year extended follow-up of the MUST trial found that systemic corticosteroid and immunosuppressive therapy led to better visual acuity outcomes and fewer complications than intravitreous fluocinolone acetonide implants in eyes with uveitis. The Multicenter Uveitis Steroid Treatment (MUST) trial compared the outcomes of these two strategies over a period of 2 years. Primary outcomes showed equal improvement of visual acuity, with an early statistically significant advantage of the implant at 6 months in patients with severe noninfectious intermediate, posterior or pan-uveitis.